JP2017533248A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533248A5
JP2017533248A5 JP2017525075A JP2017525075A JP2017533248A5 JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5 JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridin
oxo
enyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525075A
Other languages
English (en)
Japanese (ja)
Other versions
JP6669744B2 (ja
JP2017533248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060003 external-priority patent/WO2016077378A1/en
Publication of JP2017533248A publication Critical patent/JP2017533248A/ja
Publication of JP2017533248A5 publication Critical patent/JP2017533248A5/ja
Application granted granted Critical
Publication of JP6669744B2 publication Critical patent/JP6669744B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525075A 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン Expired - Fee Related JP6669744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077703P 2014-11-10 2014-11-10
US62/077,703 2014-11-10
PCT/US2015/060003 WO2016077378A1 (en) 2014-11-10 2015-11-10 Substituted pyrrolopyrdines as inhibitors of bromodomain

Publications (3)

Publication Number Publication Date
JP2017533248A JP2017533248A (ja) 2017-11-09
JP2017533248A5 true JP2017533248A5 (OSRAM) 2018-12-20
JP6669744B2 JP6669744B2 (ja) 2020-03-18

Family

ID=54608969

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525075A Expired - Fee Related JP6669744B2 (ja) 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン

Country Status (6)

Country Link
US (1) US10183009B2 (OSRAM)
EP (1) EP3218375B1 (OSRAM)
JP (1) JP6669744B2 (OSRAM)
CN (3) CN116003409A (OSRAM)
MA (1) MA40943A (OSRAM)
WO (1) WO2016077378A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR20240134245A (ko) 2014-04-23 2024-09-06 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CN107108613B (zh) 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
EP4234554A3 (en) 2016-06-20 2023-12-27 Incyte Corporation Crystalline solid forms of a bet inhibitor
CN110167939B (zh) * 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
EP3609896A4 (en) * 2017-04-14 2020-11-04 AbbVie Inc. BROMODOMAIN INHIBITORS
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
IL275478B2 (en) * 2017-12-20 2024-06-01 Betta Pharmaceuticals Co Ltd A preparation that functions as a bromodomain protein inhibitor, and the composition
CN109970733B (zh) * 2017-12-28 2020-05-08 新发药业有限公司 一种维罗非尼及其类似物的简便制备方法
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
CN110577526B (zh) * 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
CN110372693B (zh) * 2018-07-04 2022-05-03 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN110776508B (zh) 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN110818609A (zh) * 2018-08-11 2020-02-21 中国药科大学 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途
US20220079951A1 (en) * 2018-12-20 2022-03-17 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
EP3917526A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021155225A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
CN115667254A (zh) * 2020-05-21 2023-01-31 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
CN116322780A (zh) * 2020-07-29 2023-06-23 福宏治疗公司 化合物及其用途
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4540226A1 (en) 2022-06-16 2025-04-23 Amphista Therapeutics Ltd Bifunctional molecules for targeted protein degradation
EP4587126A1 (en) 2022-09-13 2025-07-23 Amphista Therapeutics Ltd Compounds for targeted protein degradation
WO2024193527A1 (zh) * 2023-03-20 2024-09-26 山东新时代药业有限公司 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物
WO2025117674A1 (en) * 2023-11-28 2025-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
GB202319256D0 (en) 2023-12-15 2024-01-31 Amphista Therapeutics Ltd Novel compounds for targeted protein degradation
WO2025191109A1 (en) 2024-03-13 2025-09-18 Amphista Therapeutics Limited Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
MX9700535A (es) 1994-07-21 1997-04-30 Akzo Nobel Nv Formulaciones de peroxido de cetona ciclico.
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK0980244T3 (da) 1997-05-06 2003-09-29 Wyeth Corp Anvendelse af quinazoline forbindelser til behandling af polycystisk nyresygdom
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CA2306155A1 (en) 1997-11-06 1999-05-20 Philip Frost Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
JP2007291059A (ja) * 2005-11-21 2007-11-08 Japan Tobacco Inc ヘテロ環化合物およびその医薬用途
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20140094456A1 (en) * 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
BR112015022674A2 (pt) 2013-03-11 2017-07-18 Abbvie Inc inibidores de bromodomínio
JP6419735B2 (ja) * 2013-03-12 2018-11-07 アッヴィ・インコーポレイテッド 四環系ブロモドメイン阻害剤
CN104211639A (zh) 2013-06-05 2014-12-17 中国科学院上海药物研究所 一类炔基杂环类化合物及其应用
EA201690007A1 (ru) 2013-06-12 2016-04-29 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
SG11201510678TA (en) * 2013-06-28 2016-01-28 Abbvie Inc Bromodomain inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
KR102373700B1 (ko) * 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
KR20240134245A (ko) * 2014-04-23 2024-09-06 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
CN107108613B (zh) * 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
US9695200B2 (en) * 2015-01-23 2017-07-04 Confluence Life Sciences, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
JP6512051B2 (ja) * 2015-09-28 2019-05-15 株式会社Jvcケンウッド 端末装置、通信システム、通信方法、プログラム

Similar Documents

Publication Publication Date Title
JP2017533248A5 (OSRAM)
JP2017533249A5 (OSRAM)
JP2017533250A5 (OSRAM)
JP2019516759A5 (OSRAM)
KR101258426B1 (ko) 세포 증식과 관련된 질환 치료용 배합물
JP2017530176A5 (OSRAM)
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
TWI699355B (zh) 喹唑啉化合物
Roth et al. Nintedanib: from discovery to the clinic
TWI556820B (zh) Hsp90抑制劑之組合
JP6669745B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
TWI324159B (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
JP2017537100A5 (OSRAM)
CN111743901B (zh) 喷雾干燥制剂
BRPI0813999A2 (pt) ciclopentanos de pirimidil como inibidores de akt proteína cinase
JP2017526696A5 (OSRAM)
JP2018510851A5 (OSRAM)
WO2022076917A1 (en) Modulators of cell proliferation and uses thereof
CN104055778A (zh) 用于癌症疾病治疗的二氢蝶啶酮
JP2019512535A5 (OSRAM)
JP2017525740A5 (OSRAM)
JP2010523677A (ja) 癌の治療のためのPI3Kα阻害剤としてのピリド[2,3−D]ピリミジン−7−オン
JP2017501983A5 (OSRAM)
JP2015514796A5 (OSRAM)
AU2013254468A1 (en) Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg